CytoDyn CEO Nader Pourhassan is already under fire for the timing of lucrative sales of company stock. On Thursday night, Pourhassan found himself with a new problem: An admission that CytoDyn misled investors about a completed drug marketing application to the Food and Drug Administration.
The biotech’s lead drug, leronlimab, an investigational treatment for patients with HIV, has not been submitted for approval to the FDA, as the company previously claimed.
About the Author Reprints
